Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

Uno studio per conoscere il farmaco di studio denominato PF-08634404 in combinazione con la chemioterapia nel cancro gastroesofageo

9 ottobre 2026 aggiornato da: Pfizer

UNO STUDIO INTERVENTISTICO DI FASE 2/3 DI PF-08634404 IN COMBINAZIONE CON CHEMIOTERAPIA IN PARTECIPANTI NAÏVE AL TRATTAMENTO CON ADENOCARCINOMA GASTRICO, DELLA GIUNZIONE GASTROESOFAGEA O DELL'ESOFAGO LOCALMENTE AVANZATO O METASTATICO

This study is being done to learn more about a new medicine called PF-08634404 and how well it works when given with chemotherapy to people with gastroesophageal cancer that is locally advanced (spread to nearby tissues) or has spread to other parts of the body.

To join the study, participants must meet the following conditions:

Be 18 years or older. Have locally advanced or metastatic gastric, gastroesophageal junction or esophageal adenocarcinoma Be treatment naïve for advanced or metastatic disease Be in good physical condition and have healthy organs based on medical tests.

The study has two parts:

  • In the first part, researchers will check how safe the study medicine in combination with chemotherapy is and how well people respond to it.
  • In the second part, they will compare study medicine plus chemotherapy to another approved treatment (nivolumab plus chemotherapy) to see which works better.

The treatment will be given in repeated time periods called cycles.

Panoramica dello studio

Tipo di studio

Interventistico

Iscrizione (Stimato)

840

Fase

  • Fase 2
  • Fase 3

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Ontario
      • London, Ontario, Canada, N6A 5W9
        • Non ancora reclutamento
        • London Health Sciences Centre - Verspeeten Family Cancer Centre
    • Guangdong
      • Guangzhou, Guangdong, Cina, 510655
        • Reclutamento
        • The Sixth Affiliated hospital, Sun Yat-sen University
    • Hubei
      • Wuhan, Hubei, Cina, 430079
        • Reclutamento
        • Hubei Cancer Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, Cina, 200031
        • Reclutamento
        • Zhongshan Hospital,Fudan University
    • Sichuan
      • Chengdu, Sichuan, Cina, 610041
        • Reclutamento
        • Sichuan Cancer hospital
      • Paris, Francia, 75015
        • Reclutamento
        • Hôpital Européen Georges Pompidou
    • Aichi-ken
      • Nagoya, Aichi-ken, Giappone, 464-8681
        • Reclutamento
        • Aichi Cancer Center
    • Central District
      • Petah Tikva, Central District, Israele, 4941492
        • Reclutamento
        • Rabin Medical Center
    • HA Merkaz
      • Ramat Gan, HA Merkaz, Israele, 5265601
        • Reclutamento
        • Sheba Medical Center
    • TELL ABĪB
      • Tel Aviv, TELL ABĪB, Israele, 6423906
        • Reclutamento
        • Sourasky Medical Center
      • Milan, Italia, 20141
        • Reclutamento
        • Istituto Europeo di Oncologia IRCCS
      • Bayamón, Porto Rico, 00959
        • Reclutamento
        • Pan American Center for Oncology Trials, LLC - Bayamón Office
    • United States
      • Manati, United States, Porto Rico, 00674
        • Reclutamento
        • Pan American Center for Oncology Trials, LLC - Manati Office
    • Barcelona [barcelona]
      • Barcelona, Barcelona [barcelona], Spagna, 08035
        • Reclutamento
        • Hospital Universitari Vall d'Hebron
    • Madrid, Comunidad de
      • Madrid, Madrid, Comunidad de, Spagna, 28041
        • Reclutamento
        • Hospital Universitario 12 de Octubre
    • Ourense [orense]
      • Ourense, Ourense [orense], Spagna, 32005
        • Non ancora reclutamento
        • Complexo Hospitalario Universitario de Ourense
    • California
      • Atascadero, California, Stati Uniti, 93422
        • Reclutamento
        • UCLA Hematology/Oncology - Atascadero
      • Burbank, California, Stati Uniti, 91505
        • Reclutamento
        • UCLA Hematology/Oncology - Burbank
      • Encino, California, Stati Uniti, 91436
        • Reclutamento
        • UCLA Hematology/Oncology - Encino
      • Marina del Rey, California, Stati Uniti, 90292
        • Reclutamento
        • UCLA Hematology/Oncology - Marina del Rey
      • Porter Ranch, California, Stati Uniti, 91326
        • Reclutamento
        • UCLA Hematology/Oncology - Porter Ranch
      • San Francisco, California, Stati Uniti, 94158
        • Non ancora reclutamento
        • UCSF Helen Diller Family Comprehensive Cancer Center
      • San Francisco, California, Stati Uniti, 94158
        • Non ancora reclutamento
        • UCSF Investigational Drugs Pharmacy
      • San Luis Obispo, California, Stati Uniti, 93401
        • Reclutamento
        • UCLA Hematology/Oncology - San Luis Obispo
      • Santa Barbara, California, Stati Uniti, 93101
        • Reclutamento
        • UCLA Hematology/Oncology - Santa Barbara
      • Santa Monica, California, Stati Uniti, 90404
        • Reclutamento
        • UCLA Hematology/Oncology - Santa Monica
    • Colorado
      • Aurora, Colorado, Stati Uniti, 80012
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Boulder, Colorado, Stati Uniti, 80303
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Centennial, Colorado, Stati Uniti, 80112
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Colorado Springs, Colorado, Stati Uniti, 80907
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Colorado Springs, Colorado, Stati Uniti, 80923
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Denver, Colorado, Stati Uniti, 80218
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Denver, Colorado, Stati Uniti, 80220
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Englewood, Colorado, Stati Uniti, 80113
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Lakewood, Colorado, Stati Uniti, 80228
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Littleton, Colorado, Stati Uniti, 80120
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Lone Tree, Colorado, Stati Uniti, 80124
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Longmont, Colorado, Stati Uniti, 80504
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Pueblo, Colorado, Stati Uniti, 81003
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
      • Thornton, Colorado, Stati Uniti, 80260
        • Reclutamento
        • Rocky Mountain Cancer Centers, LLP
    • Florida
      • Daytona Beach, Florida, Stati Uniti, 32117
        • Non ancora reclutamento
        • Florida Cancer Specialists
      • Fleming Island, Florida, Stati Uniti, 32003
        • Non ancora reclutamento
        • Florida Cancer Specialists
      • Palm Beach Gardens, Florida, Stati Uniti, 33410
        • Non ancora reclutamento
        • Florida Cancer Specialists
      • Sebring, Florida, Stati Uniti, 33870
        • Non ancora reclutamento
        • Florida Cancer Specialists
      • Wellington, Florida, Stati Uniti, 33414
        • Non ancora reclutamento
        • Florida Cancer Specialists
      • West Palm Beach, Florida, Stati Uniti, 33401
        • Non ancora reclutamento
        • Florida Cancer Specialists
    • Illinois
      • Arlington Heights, Illinois, Stati Uniti, 60005
        • Reclutamento
        • Illinois Cancer Specialists
      • Bloomington, Illinois, Stati Uniti, 61704
        • Reclutamento
        • Illinois CancerCare - Bloomington
      • Chicago, Illinois, Stati Uniti, 60631
        • Reclutamento
        • Illinois Cancer Specialists
      • Galesburg, Illinois, Stati Uniti, 61401
        • Reclutamento
        • Illinois CancerCare - Galesburg
      • Niles, Illinois, Stati Uniti, 60714
        • Reclutamento
        • Illinois Cancer Specialists
      • Ottawa, Illinois, Stati Uniti, 61350
        • Reclutamento
        • Illinois CancerCare-Ottawa-Fox River Cancer Center
      • Pekin, Illinois, Stati Uniti, 61554
        • Reclutamento
        • Illinois CancerCare-Pekin
      • Peoria, Illinois, Stati Uniti, 61615
        • Reclutamento
        • Illinois CancerCare, P.C.
      • Peru, Illinois, Stati Uniti, 61354
        • Reclutamento
        • Illinois CancerCare-Peru - Valley Regional Cancer Center
      • Washington, Illinois, Stati Uniti, 61571
        • Reclutamento
        • Illinois CancerCare-Washington
    • Maryland
      • Annapolis, Maryland, Stati Uniti, 21401
        • Reclutamento
        • Maryland Oncology Hematology, P.A.
      • Bethesda, Maryland, Stati Uniti, 20817
        • Reclutamento
        • Maryland Oncology Hematology, P.A.
      • Brandywine, Maryland, Stati Uniti, 20613
        • Reclutamento
        • Maryland Oncology Hematology, P.A.
      • Columbia, Maryland, Stati Uniti, 21044
        • Reclutamento
        • Maryland Oncology Hematology, P.A.
      • Germantown, Maryland, Stati Uniti, 20876
        • Reclutamento
        • Maryland Oncology Hematology, P.A.
      • Largo, Maryland, Stati Uniti, 20774
        • Reclutamento
        • Maryland Oncology Hematology, P.A.
      • Rockville, Maryland, Stati Uniti, 20850
        • Reclutamento
        • Maryland Oncology Hematology, P.A.
      • Silver Spring, Maryland, Stati Uniti, 20904
        • Reclutamento
        • Maryland Oncology Hematology, P.A.
    • Nevada
      • Reno, Nevada, Stati Uniti, 89502
        • Reclutamento
        • Renown Regional Medical Center
      • Reno, Nevada, Stati Uniti, 89502
        • Reclutamento
        • Renown Health Medical Oncology
      • Reno, Nevada, Stati Uniti, 89502
        • Reclutamento
        • Renown Office of Clinical Research
    • New Jersey
      • Morristown, New Jersey, Stati Uniti, 07960
        • Non ancora reclutamento
        • Atlantic Health System
      • Summit, New Jersey, Stati Uniti, 07901
        • Non ancora reclutamento
        • Atlantic Health System / Overlook Medical Center
    • New York
      • Long Island City, New York, Stati Uniti, 11101
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center Pharmacy (IMP ship to address)
      • Long Island City, New York, Stati Uniti, 11101
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center Pharmacy (IMP storage location)
      • New York, New York, Stati Uniti, 10065
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - Main Campus
      • New York, New York, Stati Uniti, 10021
        • Reclutamento
        • Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
      • New York, New York, Stati Uniti, 10022
        • Reclutamento
        • Rockefeller Outpatient Pavilion (53rd Street)
    • Ohio
      • Cincinnati, Ohio, Stati Uniti, 45245
        • Reclutamento
        • Oncology Hematology Care Clinical Trials, LLC
      • Cincinnati, Ohio, Stati Uniti, 45242
        • Reclutamento
        • Oncology Hematology Care Clinical Trials, LLC
      • Cincinnati, Ohio, Stati Uniti, 45211
        • Reclutamento
        • Oncology Hematology Care Clinical Trials, LLC
      • Fairfield, Ohio, Stati Uniti, 45014
        • Reclutamento
        • Oncology Hematology Care Clinical Trials, LLC
    • Pennsylvania
      • Bensalem, Pennsylvania, Stati Uniti, 19020
        • Reclutamento
        • Alliance Cancer Specialists, PC
      • Doylestown, Pennsylvania, Stati Uniti, 18901
        • Reclutamento
        • Alliance Cancer Specialists, PC
      • Horsham, Pennsylvania, Stati Uniti, 19044
        • Reclutamento
        • Alliance Cancer Specialists, PC
      • Langhorne, Pennsylvania, Stati Uniti, 19047
        • Reclutamento
        • Alliance Cancer Specialists, PC
      • Media, Pennsylvania, Stati Uniti, 19063
        • Reclutamento
        • Alliance Cancer Specialists, PC
      • Sellersville, Pennsylvania, Stati Uniti, 18960
        • Reclutamento
        • Alliance Cancer Specialists, PC
      • Wynnewood, Pennsylvania, Stati Uniti, 19096
        • Reclutamento
        • Alliance Cancer Specialists, PC
    • Texas
      • Irving, Texas, Stati Uniti, 75063
        • Reclutamento
        • US Oncology Investigational Products Center (IPC)
    • Virginia
      • Arlington, Virginia, Stati Uniti, 22201
        • Reclutamento
        • Virginia Cancer Specialists, PC
      • Chesapeake, Virginia, Stati Uniti, 23320
        • Reclutamento
        • Virginia Oncology Associates
      • Fairfax, Virginia, Stati Uniti, 22031
        • Reclutamento
        • Virginia Cancer Specialists, PC
      • Hampton, Virginia, Stati Uniti, 23666
        • Reclutamento
        • Virginia Oncology Associates
      • Manassas, Virginia, Stati Uniti, 20110
        • Reclutamento
        • Virginia Cancer Specialists, PC
      • Newport News, Virginia, Stati Uniti, 23606
        • Reclutamento
        • Virginia Oncology Associates
      • Norfolk, Virginia, Stati Uniti, 23502
        • Reclutamento
        • Virginia Oncology Associates
      • Reston, Virginia, Stati Uniti, 20190
        • Reclutamento
        • Virginia Cancer Specialists, PC
      • Virginia Beach, Virginia, Stati Uniti, 23456
        • Reclutamento
        • Virginia Oncology Associates
      • Woodbridge, Virginia, Stati Uniti, 22191
        • Reclutamento
        • Virginia Cancer Specialists, PC
    • Washington
      • Seattle, Washington, Stati Uniti, 98195
        • Reclutamento
        • University of Washington Medical Center
      • Seattle, Washington, Stati Uniti, 98109
        • Reclutamento
        • Fred Hutchinson Cancer Center
      • Seattle, Washington, Stati Uniti, 98104
        • Reclutamento
        • Harborview Medical Center
      • Tainan, Taiwan, 704302
        • Reclutamento
        • National Cheng Kung University Hospital
      • Taipei, Taiwan, 10002
        • Reclutamento
        • National Taiwan University Hospital
      • Taipei, Taiwan, 11217
        • Reclutamento
        • Taipei Veterans General Hospital

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Descrizione

Inclusion Criteria:

  • Histological or cytological confirmed gastric, gastroesophageal junction or esophageal adenocarcinoma.
  • Evidence of locally advanced or metastatic disease.
  • Eastern Cooperative Oncology Group performance status (ECOG) 0-1
  • No prior systemic therapy for advanced or metastatic disease.
  • Adequate hepatic, liver, and renal function
  • HER-2 negative status based on local testing
  • PD-L1 positive status based on local testing

Exclusion Criteria:

  • Participants with known active CNS metastases, including leptomeningeal, brainstem, meningeal, or spinal cord metastases or compression
  • Clinically significant risk of hemorrhage or fistula
  • Major surgery or severe trauma within 4 weeks prior to the first dose, or planned major surgery during the study
  • History of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation.
  • Any Grade ≥3 bleeding/hemorrhage events within 28 days of Cycle 1 Day 1, or prior history of clinically significant bleeding events
  • Clinically significant cardiovascular disease, or other comorbidities, within 6 months prior to first dose
  • Participants with active autoimmune diseases requiring systemic treatment within the past 2 years
  • Evidence of non-infectious or drug-induced interstitial lung disease (ILD) pneumonitis

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Scopo principale: Trattamento
  • Assegnazione: Randomizzato
  • Modello interventistico: Assegnazione parallela
  • Mascheramento: Doppio

Armi e interventi

Gruppo di partecipanti / Arm
Intervento / Trattamento
Sperimentale: Phase 2 Portion

PF-08634404 + Chemotherapy

Participants will receive PF-08634404 intravenously.

Altri nomi:
  • SSGJ-707

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Sperimentale: Phase 3: Arm A

PF-08634404 + Chemotherapy

Participants will receive PF-08634404 intravenously.

Altri nomi:
  • SSGJ-707

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Comparatore attivo: Phase 3: Arm B

Nivolumab + Chemotherapy

Participants will receive PF-08634404 intravenously in combination with Chemotherapy.

Participants will receive Nivolumab intravenously.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Phase 2: Confirmed Objective response rate (ORR) using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years

Confirmed ORR by investigator is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR) per RECIST v1.1 as assessed by investigator.

Approximately 4 years
Phase 2: Number of participants with treatment-emergent adverse events
Lasso di tempo: Through 90 days after the last study intervention; Approximately 4 years

Adverse Events (AEs) as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study intervention.

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Progression Free Survival (PFS) using RECIST 1.1 as assessed by BICR
Lasso di tempo: Approximately 4 years

PFS by BICR is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: Overall Survival (OS)
Lasso di tempo: Approximately 4 years

OS is defined as the time from the date of randomization to the date of death due to any cause.

Approximately 4 years

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Fase 2: Incidenza di Anticorpi Anti-Farmaco (ADA) contro PF-08634404
Lasso di tempo: Circa 21 mesi
Circa 21 mesi
Fase 3: Incidenza di ADA contro PF-08634404
Lasso di tempo: Circa 21 mesi
Circa 21 mesi
Fase 3: Variazione rispetto al basale del punteggio totale del Functional Assessment of Cancer Therapy - Gastric (FACT-Ga)
Lasso di tempo: Circa 4 anni
Circa 4 anni
Fase 3: Tempo fino al deterioramento definitivo nel punteggio totale FACT-Ga
Lasso di tempo: Circa 4 anni
Circa 4 anni
Fase 3: Tempo fino al deterioramento definitivo nel punteggio della sottoscala del cancro gastrico (GaCS)
Lasso di tempo: Circa 4 anni
Circa 4 anni
Phase 2: Duration of Response (DOR) using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years

DOR by investigator is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 2: Progression Free Survival (PFS) using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years

PFS by investigator is defined as the time from the date of first dose to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 2: Overall Survival (OS)
Lasso di tempo: Approximately 4 years

OS is defined as the time from the date of first dose to the date of death due to any cause.

Approximately 4 years
Phase 2: Number of participants with laboratory abnormalities
Lasso di tempo: Through 90 days after the last study intervention; Approximately 4 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed.

Through 90 days after the last study intervention; Approximately 4 years
Phase 2: Serum concentrations of PF-08634404
Lasso di tempo: Approximately 21 months

Predose and postdose concentrations of PF-08634404

Approximately 21 months
Phase 3: ORR using RECIST 1.1 as assessed by BICR
Lasso di tempo: Approximately 4 years

ORR by BICR is defined as the proportion of participants with a Best Overall Response (BOR) of confirmed CR or confirmed PR per RECIST 1.1 as assessed by BICR.

Approximately 4 years
Phase 3: ORR using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years

ORR by investigator is defined as the proportion of participants with a BOR of confirmed CR or confirmed PR per RECIST 1.1 as assessed by investigator.

Approximately 4 years
Phase 3: Progression free survival (PFS) using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years

PFS by investigator is defined as the time from the date of randomization to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, or death due to any cause, whichever occurs first

Approximately 4 years
Phase 3: DOR using RECIST 1.1 as assessed by BICR
Lasso di tempo: Approximately 4 years

DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by BICR, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: DOR using RECIST 1.1 as assessed by investigator
Lasso di tempo: Approximately 4 years

DOR is defined as the time from the first documentation of objective response (CR or PR that is subsequently confirmed) to the date of first documented disease progression per RECIST 1.1 as assessed by investigator, respectively, or death due to any cause, whichever occurs first.

Approximately 4 years
Phase 3: PFS2 (PFS after next-line therapy) by investigator
Lasso di tempo: Approximately 4 years

PFS2 is defined as the time from the date of randomization to the date of second objective disease progression or death due to any cause, whichever occurs first

Approximately 4 years
Phase 3: Number of participants with treatment-emergent adverse events
Lasso di tempo: Through 90 days after the last study intervention; Approximately 4 years

AEs as characterized by type, frequency, intensity as graded by NCI CTCAE version 5.0, timing, seriousness, and relationship to study intervention(s)

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Number of participants with laboratory abnormalities
Lasso di tempo: Through 90 days after the last study intervention; Approximately 4 years

Laboratory abnormalities as characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timing. For laboratory tests without CTCAE grade definitions, results will be categorized as normal, high, low, or not done and be listed.

Through 90 days after the last study intervention; Approximately 4 years
Phase 3: Serum concentrations of PF-08634404
Lasso di tempo: Approximately 21 months

Predose and postdose concentrations of PF-08634404

Approximately 21 months

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Investigatori

  • Direttore dello studio: Pfizer CT.gov Call Center, Pfizer

Pubblicazioni e link utili

La persona responsabile dell'inserimento delle informazioni sullo studio fornisce volontariamente queste pubblicazioni. Questi possono riguardare qualsiasi cosa relativa allo studio.

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Effettivo)

14 maggio 2026

Completamento primario (Stimato)

22 luglio 2031

Completamento dello studio (Stimato)

21 luglio 2032

Date di iscrizione allo studio

Primo inviato

30 gennaio 2026

Primo inviato che soddisfa i criteri di controllo qualità

30 gennaio 2026

Primo Inserito (Effettivo)

6 febbraio 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

13 ottobre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

9 ottobre 2026

Ultimo verificato

1 ottobre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

Sì

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

prodotto fabbricato ed esportato dagli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi